A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's

NCT06928142 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

83

Enrollment

INDUSTRY

Sponsor class

Conditions

Sjogren Disease

Interventions

BIOLOGICAL: Sibeprenlimab
OTHER: Placebo

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.